INTRODUCTION
Cancer progression is a complex, multifaceted process that involves not only intrinsic genetic changes unique to the malignant cell but also dynamic reciprocal communication between the cancer cell and stromal cells within the tumor microenvironment (1) . As cancers progress, the stromal cells become reactive, phenotypically mimicking tissues undergoing wound healing or chronic inflammation.
Indeed, many solid human cancers are characterized by desmoplasia, with high numbers of myofibroblasts (2) . These myofibroblasts often termed cancer associated fibroblasts (CAF), express tenascin C (Ten C), periostin, seprase, matrix metalloproteinases and other proteins promoting tumor procession, invasion and metastases (3) (4) (5) . Notably, Ten C has been implicated in tumor progression by facilitating metastasis (6) .
In liver, CAF likely originate from hepatic stellate cells, although CAF may also be derived from portal fibroblasts or potentially even from bone-marrow derived precursor cells (3) . Activation of hepatic stellate cells not only converts these cells into matrix producing myofibroblasts, but also enhances their susceptibility to apoptosis analogous to the activation-induced cell death observed in T-lymphocytes (7) . For example, resolution of the wound healing response in acute liver injury is associated with enhanced myofibroblast apoptosis, thereby reducing their absolute numbers in the liver (8) . By analogy, one may predict that CAF may also be uniquely sensitive to proapoptotic stimuli, suggesting that selective deletion of CAF with pro-apoptotic therapies could potentially abrogate their support of cancer cells. This in turn, would be expected to negatively affect tumor survival, growth and progression. However, selectively targeting CAF as anticancer strategy remains largely unexplored. Author Manuscript Published OnlineFirst on December 5, 2012; DOI: 10.1158/0008-5472. CAN-12-2130 Apoptosis is regulated by members of the Bcl-2 family of proteins, which control mitochondrial outer membrane permeabilization (MOMP) (9) . A pro-apoptotic subset of these proteins displays only a single Bcl-2 homology domain termed the BH3 domain.
BH3-only proteins act as initiators of cell death by either promoting activation of the multi-domain pro-apoptotic Bcl-2 proteins Bax and Bak, (10) or by neutralizing the antiapoptotic Bcl-2 proteins (9) . Given the ability of the BH3-only proteins to initiate cell death pathways, the pharmaceutical industry has developed BH3-only protein mimetics such as navitoclax (ABT-263) (11) . This small organic molecule may exert single-agent activity in selected cells despite its inability to directly activate Bax or Bak. The direct cytotoxicity by a sensitizing BH3 mimetic can be explained if the mitochondria of these cells are "primed" for cell death (12) . In one model of priming, the mitochondrial antiapoptotic proteins are nearly saturated with activator BH3-only proteins. In this model, the BH3 mimetic may displace and liberate preexisting bound activators, thus allowing them to trigger Bax or Bak oligomerization and MOMP. In an alternative model termed the "embedded together" model, anti-apoptotic proteins inhibit not only BH-3 only proteins, but also Bax or Bak within the outer mitochondrial membrane (13, 14) . In this latter model, BH3 mimetics may alter the competing equilibrium between the various Bcl-2 binding partners permitting Bax or Bak activation and MOMP.
Herein, we used cholangiocarcinoma as a model of a highly desmoplastic cancer to examine the role of pro-apoptotic signaling in targeting CAF. Our results suggest that compared to quiescent fibroblasts and CCA cells, CAF are significantly more susceptible to cell death by navitoclax in vitro and in vivo. Moreover, our data indicate that mitochondria from CAF appear to be primed for cell death. These mechanistic insights (22) . The hCAF cell lines were karyotyped to confirm a normal karyotype.
Expansion media consisted of DMEM with 10% fetal bovine serum, 100 U/ml penicillin, 100 g/ml streptomycin. Lakes, NJ) crosslinked beads were prepared as previously described (23) with initial mean body weights ranging between 180 and 230 g, as we have previously described in detail (27) . Buprenorphine (0.05 mg/kg SubQ) was used for postoperative analgesia. For apoptosis studies, navitoclax (5 mg/kg) or vehicle was given i.p. once daily for 2 consecutive days starting 7 d after tumor implantation. Twenty-four hours after CAN-12-2130 receiving the second treatment, the rats were euthanized and the livers were removed for analysis. For tumor size and metastasis analysis, navitoclax (5 mg/kg) or vehicle was given i.p. once daily for ten consecutive days starting 7 d after tumor implantation.
Immunoprecipitation of Bcl
Animals were sacrificed at day 18 and the livers were removed for analysis. Survival studies were performed as regulated by the Institutional Animal Care and Use Committee and animals were euthanized according to defined endpoints (weight loss > 25% of original body weight, disabilitating tumor mass, inability to reach food or water, moribund appearance).
Statistical analysis. Data represent at least three independent experiments using cells from a minimum of three separate isolations and are expressed as means ± SEM.
Differences between groups were compared using two-tailed Student's t tests or χ2 tests.
Survival data were analyzed and Kaplan-Meier graphs were generated using GraphPad Prism software 6 (GraphPad Software, La Jolla, CA). (29), was not expressed by CAF or even quiescent fibroblasts, although it was expressed by CCA, as previously described (25) (Fig. 2B ). Bax was consistently up-regulated in the myofibroblasts as compared to quiescent fibroblasts ( Fig. 2A) , which is likely due to post-translational regulatory differences as Bax mRNA levels were similar between quiescent fibroblasts and the activated phenotype (data not shown). LX-2 cells also displayed an increase of activated Bax compared to quiescent fibroblasts following navitoclax treatment (Fig. 2C) . Finally, shRNA targeted knockdown of Bax but not Bak reduced navitoclax-induced cytotoxicity of myofibroblastic LX-2 cells (Fig. 2D ).
Although Mcl-1 has been previously identified as a resistance factor for navitoclax cytotoxicity (30), we further verified the effect of Mcl-1 on navitoclax sensitivity in our paradigms ( Liver myofibroblasts display mitochondrial priming for cell death.
Navitoclax is incapable of directly inducing Bax activation (11, 31) . Moreover, quiescent fibroblasts were also resistant to navitoclax cell killing despite failure to express Mcl-1.
To reconcile these observations, we postulated that CAF mitochondria were primed for cell death (32) . Mitochondrial priming refers to the empiric observation that activated or transformed cells have a reduced threshold for BH3 peptide-or BH3 mimetic-induced mitochondrial release of apoptogenic factors such as Smac and cytochrome c (33). For these studies we employed the LX-2 cells, given their ability to be easily transfected.
Upon navitoclax treatment, we observed substantial Smac release from isolated cellular heavy membranes enriched in mitochondria (Fig. 4A ) as well as into the cytoplasm of whole cells (Fig. 4B) . However, Smac release was not observed in shBax cells (Fig. 4C ).
Mitochondria from CCA cells did not display release of apoptogenic factors upon exposure to navitoclax (Fig. 4D) . Finally, consistent with being primed for cell death, the LX-2 cells but not quiescent fibroblasts nor CCA cells underwent mitochondrial membrane depolarization following navitoclax treatment and this effect was abolished in shBax LX-2 cells (Fig. 4E) . To further examine mechanisms responsible for this observed priming, mitochondrial enriched heavy membrane fractions obtained from CCA, LX-2 and hCAF cells were profiled for activator BH3-only proteins (Bid, Bim and Puma), and Bax and Bak by immunoblot analysis (Fig. 5A ). Increased Bax, Bid and Bim were identified in the mitochondrial fraction of myofibroblasts but not CCA cells. In accordance with other studies of priming (30) , navitoclax treatment of LX-2 cells decreased Bim binding to Bcl-X L as examined by immunoprecipitation studies (Fig. 5B ).
These observations support the concept that the activated state of CAF is associated with 
immunofluorescence staining for the tumor stroma markers α-SMA and Ten C (Fig. 6C ).
This observation was also confirmed by quantitative analysis of α-SMA and Ten C mRNA expression in the tumor samples (Fig. 6D) . Finally, we examined the potential tumor suppressing effect of navitoclax treatment in this model. In vehicle and navitoclax treated rats, tumor weight and metastases were examined after 10 days of treatment, initiated 7 days after tumor implantation. Mean gross tumor wet weight (Fig. 7A ) and mean tumor-liver weight ratio (Fig. 7B) were reduced in the navitoclax-treated animals.
Peritoneal metastases were also reduced in this group (Fig. 7C) . The navitoclax treatment associated tumor suppressive effects also translated into an improved animal survival (Fig. 7D) . The morphometric analysis revealed an altered tumor composition after 10 days of treatment, namely a reduction in the ratio of α-SMA and Ten C positive stroma to tumor area (Fig. 7E) . Histologically the tumors appeared less desmoplastic with larger contiguous areas of tumor cells rather than isolated tumor glands typical for CCA (Fig. 7F) . Finally, we were also able to demonstrate Bax activation and loss of mitochondrial Smac in CAF following navitoclax treatment for 48 hrs, thereby, suggesting the mechanisms of navitoclax-mediated CAF cytotoxicity in vivo parallels that observed in vitro (Supplemental Fig. 5 ). Taken together, these observations suggest navitoclax impairs tumor growth and metastasis by depleting the tumor stroma of CAF, thereby reducing the extent of growth supporting CCA tumor stroma. Indeed, quiescent fibroblasts were also resistant to navitoclax cytotoxicity despite their lacking of Mcl-1 expression. These observations suggest CAF may also be primed for cell death.
DISCUSSION
In one model, mitochondrial priming is considered to be a state in which the capacity of anti-apoptotic Bcl-2 proteins to sequester pro-apoptotic BH3 only proteins or bind Bax/Bak is almost completely exhausted (32) . In this situation minimal shifts of the Bcl-2 equilibrium can cause cells to rapidly enter apoptosis (37). By binding to the antiapoptotic Bcl-2 proteins Bcl-2 and Bcl-X L , navitoclax displaces sequestered BH3 proteins like Bim from these antiapoptotic proteins and enables them to activate Bax and Bak, inducing apoptosis (14) . Indeed, we were able to demonstrate Bim displacement from Bcl-X L following navitoclax treatment in our current studies. In an alternative 
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